Hormonal
Rosiglitazone reduces liver fat content and increases insulin clearance in patients with type 2 diabetes, whereas metformin improves hepatic insulin sensitivity without altering liver fat.
For patients with type 2 diabetes, rosiglitazone (a PPAR-gamma agonist) significantly reduces liver fat and improves how the liver clears insulin, leading to better peripheral glucose uptake. Metformin, while effective for lowering blood sugar and improving hepatic insulin sensitivity, does not reduce liver fat. This suggests that the choice of medication may depend on whether reducing liver fat is a primary therapeutic goal.
In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance... Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.
Why this rating
Double-blind randomized controlled trial with objective measures (proton spectroscopy, clamps), though sample size is small (n=20).
Source
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Mirja Tiikkainen et al. · Diabetes · 2004
DOI 10.2337/diabetes.53.8.2169
More from this paper
- Rosiglitazone increases insulin clearance in patients with type 2 diabetes, which contributes to the decrease in fasting serum insulin concentrations.Good
- Rosiglitazone increases serum adiponectin concentrations and adipose tissue gene expression of PPAR-gamma, adiponectin, and lipoprotein lipase, whereas metformin does not.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →